Ergoteles LLC: CMBT position timeline
Available 13F reports, 13D and 13G stakes and each Form 3, 4 and 5 line of Ergoteles LLC on CMBT, newest first. How the timeline and the estimate are built.
Ergoteles LLC held 0 CMBT shares at 2023-09-30 per its 13F-HR filed 2023-11-14.
the latest 13F is the newest step
- period ended2023-09-3013F 0 sharesChange vs previous 13F -38,411 shares
13F-HR 0001569136-23-000005 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
Exited: the 13F for this period no longer lists the position.
- period ended2023-06-3013F 38,411 sharesChange vs previous 13F -57,589 shares
0.03% of the 13F portfolio, value $584,615.
13F-HR 0001569136-23-000004 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2023-03-3113F 96,000 sharesChange vs previous 13F -742,304 shares
0.06% of the 13F portfolio, value $1,611,840.
13F-HR 0001569136-23-000002 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2022-12-3113F 838,304 sharesChange vs previous 13F +396,686 shares
0.52% of the 13F portfolio, value $14,284,700.
13F-HR 0001569136-23-000001 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2022-09-3013F 441,618 sharesChange vs previous 13F +253,818 shares
0.24% of the 13F portfolio, value $6,797,000.
13F-HR 0001569136-22-000007 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).
- period ended2022-06-3013F 187,800 sharesChange vs previous 13F not available
0.07% of the 13F portfolio, value $2,240,000.
13F-HR 0001569136-22-000006 filed by Ergoteles LLC
Filed (acceptance time not in the bulk data set), ingestedAcceptance time not in the bulk data set (spec §4.2).